The FDA approved an oral combination of meloxicam and rizatriptan (Symbravo) to treat adults with acute migraine with or ...

The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday.

Discover how ayurveda, an ancient healing system, can help you live better with migraine. Discover doshas, dietary strategies ...

(HealthDay News) — Propranolol is associated with a reduced risk for overall stroke among women with migraine, with a more pronounced protective effect for ischemic stroke, according to a study ...

The pharmaceutical giant Pfizer will pay nearly $60 million to resolve charges that a company it acquired paid kickbacks so ...

The novel formulation of rizatriptan and meloxicam (Symbravo, Axome Therapeutics) is for the acute treatment of migraine with ...

Patti Smith collapsed onstage while performing in Brazil on Wednesday, Jan. 29. She later told fans she was "absolutely fine.

A history of migraine, with or without aura, was a significant risk factor for open-angle glaucoma onset among a cohort of ...

For patients with migraine, the clinical benefits of propranolol, a beta-blocker medication, may extend beyond just migraine ...

Meloxicam is a nonsteroidal, anti-inflammatory molecule developed with Axsome’s Molecular Solubility Enhanced Inclusion ...

The Food and Drug Administration (FDA) has approved Symbravo ® (meloxicam/rizatriptan) for the acute treatment of migraine with or without aura in adults.

The global prevalence and incidence of migraine significantly increased from 1990 to 2021, with faster growth rates predicted in men and adolescents through 2050.